Force Thomas, Krause Daniela S, Van Etten Richard A
Center for Translational Medicine and Cardiology Division, Department of Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
Nat Rev Cancer. 2007 May;7(5):332-44. doi: 10.1038/nrc2106.
Cancer therapy has progressed remarkably in recent years. In no area has this been more apparent than in the development of "targeted therapies", particularly those using drugs that inhibit the activity of certain tyrosine kinases, activating mutations or amplifications of which are causal, or strongly contributory, to tumorigenesis. However, some of these therapies have been associated with toxicity to the heart. Here we summarize what is known about the cardiotoxicity of cancer drugs that target tyrosine kinases. We focus on basic mechanisms through which interruption of specific signalling pathways leads to cardiomyocyte dysfunction and/or death, and contrast this with therapeutic responses in cancer cells.
近年来，癌症治疗取得了显著进展。这一点在“靶向治疗”的发展中最为明显，尤其是那些使用抑制某些酪氨酸激酶活性的药物，这些激酶的激活突变或扩增是肿瘤发生的原因或重要促成因素。然而，其中一些疗法与心脏毒性有关。在此，我们总结了关于靶向酪氨酸激酶的癌症药物心脏毒性的已知情况。我们关注特定信号通路中断导致心肌细胞功能障碍和/或死亡的基本机制，并将其与癌细胞的治疗反应进行对比。
